- Report
- September 2020
- 65 Pages
Global
€1244EUR$1,318USD£1,068GBP
- Report
- April 2018
United States
From €7549EUR$7,995USD£6,476GBP
- Report
- January 2024
- 87 Pages
Global
From €3500EUR$3,971USD£3,108GBP
Golimumab is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Golimumab is administered as an intravenous infusion or subcutaneous injection.
Golimumab is one of several drugs used to treat immune disorders. Other drugs used to treat these conditions include biologics such as adalimumab, etanercept, and infliximab, as well as non-biologic drugs such as methotrexate and corticosteroids.
Golimumab is marketed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. Other companies in the market include AbbVie, Amgen, and Pfizer. Show Less Read more